Our R&D Specialisms

Ipsen has a leading-edge technological platform in toxins, in which we stand out for our acknowledged expertise. This specialist knowledge also opens the door to the possibility of strong external partnerships in the field. With their unique properties, toxin molecules offer potential in the treatment of neuromuscular disorders, as well as for pain and aesthetic medicine.


Botulinum Toxins

Ipsen scientists have spent 25 years researching the mechanisms and potential applications of botulinum toxin type A. This complex protein is an extremely powerful neurotoxin produced by the Clostridium botulinum bacterium. Now used in the treatment of spasticity, botulinum toxin inhibitors make it an effective treatment for conditions affecting the junction between the muscle and the nerve, at the root of hypercontraction of some parts of the body. This unique molecule has a much broader range of potential therapeutic applications in many areas, mainly in neurology, but also in oncology, endocrinology and aesthetic medicine.

Ipsen is one of the very few companies to master the manufacture and control of this product, together with the technologies required to explore new applications and to develop new toxin-based products.


Recombinant Toxins

Produced conventionally by the extraction of the bacterial strains obtained from cultures, new techniques open the way for recombinant production of the toxins. Introduced into the bacterial strain, genes provide new sequencing and offer the potential for “on-demand” modification of the properties of the toxins.

Based in Milton Park, Oxford, in the UK, Ipsen Bioinnovation (formerly known as Syntaxin) is a leader in the field of recombinant botulinum toxin technology with expertise in natural recombinant botulinum toxins and modified recombinant botulinum toxins. This R&D center is at the forefront of Ipsen’s expertise thanks to a platform of highly differentiated and innovative toxins with 75 patents granted and over 130 patents pending. Ipsen has also started collaborating with the Harvard Medical School on research to explore novel recombinant botulinum toxins for the treatment of serious neurological disorders.


Percentage of sales invested in R&D in 2016